Pulmonary Combined Large Cell Neuroendocrine Carcinoma.
diagnosis
pathological characteristics
pulmonary combined large cell neuroendocrine carcinoma (CLCNEC)
targeted therapy
therapy
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
08
2022
accepted:
25
10
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Pulmonary combined large-cell neuroendocrine carcinoma (CLCNEC) is a rare neuroendocrine tumor pertained to lung large cell neuroendocrine carcinoma (LCNEC) with aggressive behavior and poor prognosis generally. The clinical features of CLCNEC are not specific including cough, expectoration, chest distress, chest pain, etc., which are prone to have different manifestations of the mixed components. Owing to the low incidence, there are few related small-scale retrospective studies and case reports. Currently, the treatment regimen of CLCNEC mainly refers to LCNEC that complete surgical resection is preferred in the early stage and according to previous researches, platinum-based small cell lung cancer (SCLC) standard treatment regimen showed promising results in postoperative and advanced CLCNEC as compared to that of non-small cell lung cancer (NSCLC). Adenocarcinoma-CLCNEC more likely harbor driver gene mutation, and may benefit from targeted therapy. As for immunotherapy, more clinical trial data are needed to support its benefits. This article will fill the gap and will provide new insight into the clinical characteristics, pathological diagnosis and treatment endeavors of CLCNEC.
Identifiants
pubmed: 36507119
doi: 10.3389/pore.2022.1610747
pii: 1610747
pmc: PMC9726782
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610747Informations de copyright
Copyright © 2022 Li, Yang and Lu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cancer Res Ther. 2012 Jul-Sep;8(3):445-7
pubmed: 23174733
Jpn J Clin Oncol. 2011 Jun;41(6):797-802
pubmed: 21415004
Gan To Kagaku Ryoho. 2012 Sep;39(9):1439-41
pubmed: 22996787
Clin Lung Cancer. 2017 May;18(3):e197-e201
pubmed: 28024928
Front Oncol. 2021 Sep 22;11:714549
pubmed: 34631540
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Front Oncol. 2020 Dec 01;10:556194
pubmed: 33335851
Respirol Case Rep. 2022 Jun 07;10(7):e0989
pubmed: 35685848
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Clin Cancer Res. 2017 Feb 1;23(3):757-765
pubmed: 27507618
BMJ Case Rep. 2021 Dec 30;14(12):
pubmed: 34969785
Clin Lung Cancer. 2022 Jan;23(1):e9-e16.e1
pubmed: 34321190
Ann Oncol. 2013 Jun;24(6):1548-52
pubmed: 23406729
Semin Roentgenol. 2005 Apr;40(2):90-7
pubmed: 15898407
Lung Cancer. 2020 Jan;139:118-123
pubmed: 31775086
J Cancer. 2019 Jul 10;10(18):4226-4236
pubmed: 31413741
Lung Cancer. 2019 Aug;134:117-120
pubmed: 31319969
Clin Cancer Res. 2016 Jul 15;22(14):3618-29
pubmed: 26960398
J Int Med Res. 2021 Nov;49(11):3000605211055387
pubmed: 34738481
Histopathology. 2018 Mar;72(4):707-710
pubmed: 28888040
Kyobu Geka. 2006 Jun;59(6):491-5
pubmed: 16780071
Curr Oncol. 2022 Feb 03;29(2):848-852
pubmed: 35200571
J Clin Oncol. 2005 Dec 1;23(34):8774-85
pubmed: 16314638
JTO Clin Res Rep. 2022 Jan 10;3(2):100277
pubmed: 35199052
J Clin Oncol. 1989 May;7(5):607-12
pubmed: 2540288
Lung Cancer. 2012 Aug;77(2):365-70
pubmed: 22579297
J Thorac Oncol. 2018 May;13(5):707-714
pubmed: 29391287
J Thorac Oncol. 2015 Aug;10(8):1133-41
pubmed: 26039012
Clin Lung Cancer. 2016 Sep;17(5):e121-e129
pubmed: 26898325
Acta Chir Belg. 2009 Jul-Aug;109(4):489-93
pubmed: 19803261
Eur J Cardiothorac Surg. 2022 Jul 11;62(2):
pubmed: 35277717
Eur J Radiol. 2015 Nov;84(11):2332-8
pubmed: 26279139
Arch Bronconeumol. 2014 Sep;50(9):392-6
pubmed: 24685201
Am J Surg Pathol. 1991 Jun;15(6):529-53
pubmed: 1709558
J Thorac Oncol. 2014 Jun;9(6):e40-2
pubmed: 24828670
Eur J Cardiothorac Surg. 2022 Jul 11;62(2):
pubmed: 35147672
J Thorac Oncol. 2017 Mar;12(3):425-436
pubmed: 27890494
Eur J Cardiothorac Surg. 2012 Apr;41(4):841-6
pubmed: 22219429
Intern Med. 2018 Mar 1;57(5):713-716
pubmed: 29151522
Turk Thorac J. 2020 May;21(3):150-155
pubmed: 32584230
J Thorac Oncol. 2013 Jul;8(7):980-4
pubmed: 23774385